Ionis Pharmaceuticals, Inc. (IONS)

Market Cap	12.23B +135.4%
Revenue (ttm)	943.71M +33.8%
Net Income	-381.39M
EPS	-2.38
Shares Out	165.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,904,127
Open	73.97
Previous Close	75.16
Day's Range	73.15 - 75.16
52-Week Range	23.95 - 86.74
Beta	0.36
Analysts	Strong Buy
Price Target	85.91 (+16.03%)
Earnings Date	Apr 29, 2026

About IONS

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 1991
• Employees: 1,402
• Stock Exchange: NASDAQ
• Ticker Symbol: IONS
• Website: https://www.ionis.com

Financial Performance

In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.

Analyst Summary

According to 22 analysts, the average rating for IONS stock is "Strong Buy." The 12-month stock price target is $85.91, which is an increase of 16.03% from the latest price.

Price Target

$85.91

(16.03% upside)

Analyst Consensus: Strong Buy